A review summarizes how SGLT2 inhibitors, GLP-1 RAs, and other emerging therapies have transformed CKD management beyond traditional RAS inhibition.
Therapeutic revolutionSGLT2i and GLP-1 RAs provide cardiorenal protection that transforms CKD management
What the researchers found
SGLT2 inhibitors and GLP-1 RAs have transformed CKD management with cardiorenal benefits beyond glucose control, alongside emerging therapies targeting novel pathways.
Why it matters
CKD is a leading cause of death worldwide. The therapeutic revolution driven by metabolic drugs is improving outcomes for millions of patients.
How the study worked
Evidence-based narrative review of contemporary CKD therapeutics published in European Journal of Internal Medicine.
What this study cannot tell us
Narrative review — selective coverage; some emerging therapies lack mature clinical outcome data.
How to read the evidence
Evidence-based review — synthesizes clinical trial data and guideline recommendations.
When this study was published
Published 2026 in European Journal of Internal Medicine.
The bigger picture
Nephrology is experiencing its most significant therapeutic expansion in decades, shifting from supportive care to disease-modifying treatment.
Questions still open
- How should multiple CKD-protective therapies be sequenced or combined?
- Will GLP-1 RAs receive dedicated CKD indications?
Common questions
Can diabetes drugs help kidney disease?
What new kidney treatments are available?
Read the original research
Contemporary management of advanced chronic kidney disease: An evidence-based review.
European journal of internal medicine, 143, 106557
Citation
Baker, Lyle W; Ovincy, Cene; Souvalian, Levon; Hickson, LaTonya J; Chebib, Fouad T. (2026). Contemporary management of advanced chronic kidney disease: An evidence-based review.. European journal of internal medicine, 143, 106557. https://doi.org/10.1016/j.ejim.2025.106557